329 related articles for article (PubMed ID: 28988589)
21. Icodextrin: a review of its use in peritoneal dialysis.
Frampton JE; Plosker GL
Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
[TBL] [Abstract][Full Text] [Related]
22. Glycated adducts induce mesothelial cell transdifferentiation: role of glucose and icodextrin dialysis solutions.
Conti G; Amore A; Cirina P; Peruzzi L; Balegno S; Coppo R
J Nephrol; 2008; 21(3):426-37. PubMed ID: 18587733
[TBL] [Abstract][Full Text] [Related]
23. Impacts of icodextrin on integrin-mediated wound healing of peritoneal mesothelial cells.
Matsumoto M; Tamura M; Miyamoto T; Furuno Y; Kabashima N; Serino R; Shibata T; Kanegae K; Takeuchi M; Abe H; Okazaki M; Otsuji Y
Life Sci; 2012 Jun; 90(23-24):917-23. PubMed ID: 22564410
[TBL] [Abstract][Full Text] [Related]
24. [Icodextrin improve angiogenesis of peritoneal membrane in continuous ambulatory peritoneal dialysis patients].
Dai HL; Lin AW; Qian JQ; Fang W; Ni ZH; Cao LO; Lin XH; Wu QW
Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(40):2843-7. PubMed ID: 21162796
[TBL] [Abstract][Full Text] [Related]
25. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children.
van Hoeck KJ; Rusthoven E; Vermeylen L; Vandesompel A; Marescau B; Lilien M; Schroder CH
Nephrol Dial Transplant; 2003 Jul; 18(7):1383-7. PubMed ID: 12808177
[TBL] [Abstract][Full Text] [Related]
26. Icodextrin and intraperitoneal inflammation.
Moriishi M; Kawanishi H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
[TBL] [Abstract][Full Text] [Related]
27. An update on peritoneal dialysis solutions.
García-López E; Lindholm B; Davies S
Nat Rev Nephrol; 2012 Feb; 8(4):224-33. PubMed ID: 22349485
[TBL] [Abstract][Full Text] [Related]
28. [Clinical experience with icodextrin. Multicenter study].
Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Remón C; Fernández-Ruiz EJ; Pérez-Bañasco V; Benítez M; Martínez-Benavides E; Martínez-González JM; Torán D; Tejuca F; Páez C; del Pino MD
Nefrologia; 2001; 21(6):574-80. PubMed ID: 11881427
[TBL] [Abstract][Full Text] [Related]
29. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin.
Posthuma N; ter Wee PM; Niessen H; Donker AJ; Verbrugh HA; Schalkwijk CG
Perit Dial Int; 2001; 21(1):43-51. PubMed ID: 11280495
[TBL] [Abstract][Full Text] [Related]
30. Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells.
Douma CE; Hiralall JK; de Waart DR; Struijk DG; Krediet RT
Kidney Int; 1998 Apr; 53(4):1014-21. PubMed ID: 9551412
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
Opatrna S; Lysak D; Trefil L; Parker C; Topley N
Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
[TBL] [Abstract][Full Text] [Related]
32. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
33. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload.
Johnson DW; Arndt M; O'Shea A; Watt R; Hamilton J; Vincent K
BMC Nephrol; 2001 Dec; 2():2. PubMed ID: 11737871
[TBL] [Abstract][Full Text] [Related]
34. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure.
Wiggins KJ; Rumpsfeld M; Blizzard S; Johnson DW
Nephrology (Carlton); 2005 Feb; 10(1):33-6. PubMed ID: 15705179
[TBL] [Abstract][Full Text] [Related]
35. Kinetic analysis of peritoneal fluid and solute transport with combination of glucose and icodextrin as osmotic agents.
Galach M; Werynski A; Waniewski J; Freida P; Lindholm B
Perit Dial Int; 2009; 29(1):72-80. PubMed ID: 19164256
[TBL] [Abstract][Full Text] [Related]
36. Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis.
Szeto CC; Johnson DW
Semin Nephrol; 2017 Jan; 37(1):30-42. PubMed ID: 28153193
[TBL] [Abstract][Full Text] [Related]
37. Predicting the Peritoneal Absorption of Icodextrin in Rats and Humans Including the Effect of α-Amylase Activity in Dialysate.
Akonur A; Holmes CJ; Leypoldt JK
Perit Dial Int; 2015; 35(3):288-96. PubMed ID: 24584610
[TBL] [Abstract][Full Text] [Related]
38. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation.
Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB
Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606
[TBL] [Abstract][Full Text] [Related]
39. Roles of peritoneal clearance and residual kidney removal in control of uric acid in patients on peritoneal dialysis.
Xiao X; Ye H; Yi C; Lin J; Peng Y; Huang X; Wu M; Wu H; Mao H; Yu X; Yang X
BMC Nephrol; 2020 Apr; 21(1):148. PubMed ID: 32334567
[TBL] [Abstract][Full Text] [Related]
40. Novel peritoneal dialysis solutions--what are the clinical implications?
Jörres A
Blood Purif; 2012; 33(1-3):153-9. PubMed ID: 22269466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
